Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

Clinical Pharmacology & Therapeutics

Volumn 54, Issue 3, 1993, Pages 257-268

  Huang, May‐Lynn ^a,b,c   Peer, Achiel Van ^a,b,c   Woestenborghs, Robert ^a,b,c   De Coster, Roland ^a,b,c   Heykants, Jos ^a,b,c   Jansen, Arno A I ^a,b,c   Zylicz, Zbigniew ^a,b,c   Visscher, Hendrik W ^a,b,c   Jonkman, Jan H G ^a,b,c  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c PRA International USA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; HUMAN; ISOXAZOLES; MALE; MODELS, BIOLOGICAL; PIPERIDINES; PROLACTIN; RANDOM ALLOCATION; REFERENCE VALUES; RISPERIDONE;

EID: 0027436269     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.1993.146     Document Type: Article

References (0)